MediSpend® Blog

Is Maine Closing the Curtains on Transparency?

On February 18, 2011, a bill was submitted (House Paper No. 530) to "Make Certain Prescription Drug Disclosure Laws Consistent with Federal Law."  Specifically, House Paper No. 530 seeks to repeal 22 MRSA §2698-A which establishes the requirement for pharmaceutical manufacturers to report marketing costs, including certain expenditures on health care providers.  If passed, the legislation would eliminate Maine's aggregate spend reporting requirements. Presumably, the bill's sponsors recognize the redundancy in reporting requirements with the implementation of the Federal Sunshine Act. 

The bill was referred to the Committee on Health and Human Services on February 18, 2011 and has yet to be reported upon. Stay tuned for legislative updates as they occur.

 

Comments

Post new comment

We will not post or share your email address with anyone.
CAPTCHA
Enter both of the words below separated by a space.